RE:Covid implications for meetings with shareholdersI'm frequently amused by your wording, SPCEO. "
the fact that the trial is
apparantly still ongoing." ... so that is an "apparent fact"? Not sure what that means.
It is not only possible, but very likely, that this big January event is to announce the results of Phase 1a, which means it was probably concluded a couple months ago and they have been summarizing their findings and preparing for the big release (including a new investors presentation). It doesn't seem reasonable to meet with big shareholders if Phase 1a is still on a sliding schedule to which we are not being informed. Wouldn't that be the first question that big shareholders would ask?
-LT
SPCEO1 wrote:
<snip>
The biggest hint we have on the most important subject for TH right now is the fact that the trial is apparently still ongoing. So, very large doses of TH-1902 are still being given to patients and the odds that those patients with sortilin overexpressing cancers are seeing some positive impact on their tumors grows each day.
We will know soon enough.